Advice
following an abbreviated submission:
atogepant (Aquipta®) is accepted for restricted use within NHSScotland.
Indication under review: acute treatment of migraine with or without aura in adults.
SMC restriction: patients who have had inadequate symptom relief after trials of at least two triptans, or in whom triptans are contraindicated or not tolerated; and have inadequate pain relief with non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol.
Atogepant offers an additional treatment choice in the therapeutic class of calcitonin gene-related peptide receptor antagonists.
Download detailed advice423KB (PDF)
Medicine details
- Medicine name:
- atogepant (Aquipta)
- SMC ID:
- SMC2934
- Indication:
Acute treatment of migraine with or without aura in adults.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 12 October 2026